2018 Global Automated Microbiology Market: Supplier Shares & Segmentation Forecasts - Molecular Dx, Identification, Susceptibility, Blood Culture, Urine Screening and Immunodiagnostics - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “2018 Global Automated Microbiology Market: Supplier Shares and Segmentation Forecasts - Molecular Dx, Identification, Susceptibility, Blood Culture, Urine Screening, Immunodiagnostics - Competitive Landscape, Innovative Technologies, Latest Instrumen” report has been added to ResearchAndMarkets.com’s offering.
This new report is a seven-country strategic analysis of the major business opportunities emerging in the automated microbiology market during the next five years.
The report examines key trends in the U.S., five major European countries (France, Germany, Italy, Spain, UK) and Japan; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for molecular diagnostic, microbial identification, antibiotic susceptibility, blood culture, urine screening and immunodiagnostic procedures, as well as over 100 infectious disease tests by assay, application, market segment, and country; profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.
The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests.
The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies.
The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon.
The driving force behind the need for rapid reporting of microbiological test results is the clinical relevance in a time of financial austerity, a time when cost and health care effectiveness to the patient and diagnostician looms ever larger, and where after-the-fact results at high expense are coming under severe scrutiny worldwide.
This comprehensive seven-country report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology market, in evaluating emerging opportunities and developing effective business strategies.
Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D. The companies analyzed in the report include:Abbott Affymetrix Beckman Coulter/Danaher Becton Dickinson Biokit bioMerieux Bio-Rad Cepheid Decode Genetics Diadexus Diamedix DiaSorin Eiken Chemical Elitech Group Enzo Biochem Exact Sciences Fujirebio Grifols Hologic/Gen-Probe ID Biomedical/GSK Illumina Kreatech/Leica Li-Cor Biosciences Perkin Elmer/Caliper Qiagen Roche Scienion Shimadzu Siemens Sierra Molecular Takara Bio Tecan Thermo Fisher Wallac/PE Wako and more...
For more information about this report visit https://www.researchandmarkets.com/research/4j9rfx/2018_global?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005152/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:In Vitro Diagnostics
INDUSTRY KEYWORD: OTHER SCIENCE SCIENCE
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/21/2018 05:48 AM/DISC: 12/21/2018 05:48 AM